AOD-9604
Also known as: AOD-9604, Anti-Obesity Drug 9604
A modified fragment of the C-terminus of human growth hormone (residues 176-191) studied for fat-loss effects without the broader growth-promoting actions of full GH.
Last updated
Mechanism of Action
AOD-9604 is a synthetic peptide based on the lipolytic C-terminal fragment (176-191) of human growth hormone. It is thought to stimulate lipolysis and inhibit lipogenesis by acting on beta-3 adrenergic receptors in adipose tissue, mimicking GH's fat-burning effects without raising IGF-1 or affecting blood glucose. This separation of the metabolic action from the growth-promoting action is the basis of its research interest.
- Half-life
- Approximately 30 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Promotes lipolysis (fat breakdown) without raising IGF-1
- Does not appear to impair glucose tolerance
- No significant effect on growth or organ size
- Studied for cartilage and joint support
- Generally favorable tolerability in trials
Potential Side Effects
- Generally mild; injection-site reactions
- Occasional headache
- Limited evidence of strong fat-loss efficacy in humans
- Long-term safety data is limited
Common Dosing
Research literature references ~250-500 mcg daily, often dosed in the morning on an empty stomach. Educational range only, not advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Pregnancy or breastfeeding
- Hypersensitivity to the peptide
- Not approved as a weight-loss drug
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Tesamorelin
A stabilized GHRH analog FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Studied for its strong effect on visceral adipose tissue.
AOD-9604 + CJC Blend
A combination pairing the fat-loss GH fragment AOD-9604 with the GHRH analog CJC-1295, studied to layer direct lipolytic activity onto elevated endogenous growth hormone.
- View
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
2001
- View
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
2001
- View
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
2000
- View
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
2015